Genprex, Inc. (GNPX)
1.685
-0.22
(-11.32%)
USD |
NASDAQ |
Nov 17, 16:00
1.685
0.00 (0.00%)
After-Hours: 20:00
Genprex Enterprise Value : -13.03M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | -13.03M |
| November 13, 2026 | -12.81M |
| November 12, 2026 | -12.65M |
| November 11, 2026 | -12.56M |
| November 10, 2026 | -12.80M |
| November 09, 2026 | -12.84M |
| November 06, 2026 | -12.82M |
| November 05, 2026 | -12.79M |
| November 04, 2026 | -12.74M |
| November 03, 2026 | -12.53M |
| November 02, 2026 | -12.63M |
| October 30, 2026 | -12.62M |
| October 29, 2026 | -12.86M |
| October 28, 2026 | -12.90M |
| October 27, 2026 | -12.97M |
| October 26, 2026 | -13.14M |
| October 23, 2026 | -13.14M |
| October 22, 2026 | -12.93M |
| October 21, 2026 | -12.85M |
| October 20, 2026 | -12.75M |
| October 19, 2026 | -12.84M |
| October 16, 2026 | -12.78M |
| October 15, 2026 | -12.56M |
| October 14, 2026 | -12.51M |
| October 13, 2026 | -12.29M |
| Date | Value |
|---|---|
| October 12, 2026 | -12.07M |
| October 09, 2026 | -12.03M |
| October 08, 2026 | -11.99M |
| October 07, 2026 | -12.15M |
| October 06, 2026 | -12.17M |
| October 05, 2026 | -12.03M |
| October 02, 2026 | -12.14M |
| October 01, 2026 | -12.23M |
| September 30, 2026 | -11.79M |
| September 29, 2026 | -13.71M |
| September 28, 2026 | -13.73M |
| September 25, 2026 | -13.49M |
| September 24, 2026 | -13.37M |
| September 23, 2026 | -13.26M |
| September 22, 2026 | -13.36M |
| September 21, 2026 | -13.39M |
| September 18, 2026 | -13.41M |
| September 17, 2026 | -13.40M |
| September 16, 2026 | -13.43M |
| September 15, 2026 | -13.48M |
| September 14, 2026 | -13.41M |
| September 11, 2026 | -13.46M |
| September 10, 2026 | -13.46M |
| September 09, 2026 | -13.42M |
| September 08, 2026 | -13.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.321B |
| Alnylam Pharmaceuticals, Inc. | 20.79B |
| Anika Therapeutics, Inc. | 154.24M |
| Savara, Inc. | 818.43M |
| Arrowhead Pharmaceuticals, Inc. | 6.454B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.237M |
| Total Expenses (Quarterly) | 4.237M |
| EPS Diluted (Quarterly) | -5.298 |
| Earnings Yield | -3.21K% |
| Normalized Earnings Yield | -3213.70 |